Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.

CONCLUSIONS: These preliminary findings indicate that intranasal esketamine compared with placebo, given in addition to comprehensive standard-of-care treatment, may result in significantly rapid improvement in depressive symptoms, including some measures of suicidal ideation, among depressed patients at imminent risk for suicide. PMID: 29656663 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29656663?dopt=Abstract

Source: The American Journal of Psychiatry - April 16, 2018 Category: Psychiatry Authors: Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, Pinter C, Hough D, Sanacora G, Manji H, Drevets WC Tags: Am J Psychiatry Source Type: research